Day: February 22, 2024

MARIETTA, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) — Donegal Group Inc. (NASDAQ:DGICA) and (NASDAQ:DGICB) today reported its financial results for the fourth quarter and full year ended December 31, 2023. Significant items for fourth quarter of 2023 (all comparisons to fourth quarter of 2022):Net premiums earned increased 6.2% to $226.2 million Combined ratio of 106.8%, compared to 102.8% Net loss of $2.0 million, or 6 cents per Class A share, compared to net income of $3.5 million, or 11 cents per diluted Class A share Net investment gains (after tax) of $1.8 million, or 5 cents per Class A share, compared to $0.5 million, or 2 cents per diluted Class A share, are included in net (loss) incomeSignificant items for full year of 2023 (all comparisons to full year of 2022):Net premiums earned increased 7.2% to $882.1 million Combined...

WAYNE, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the fourth quarter ended December 31, 2023. Fourth quarter financial summaryRevenues of $773.9 million, reflective of five fewer shipping days year-over-year, up 2.1% compared to the prior year period; up 0.7% on a constant currency basisGAAP diluted EPS from continuing operations of $0.66, compared to $1.65 in the prior year periodAdjusted diluted EPS from continuing operations of $3.38, compared to $3.52 in the prior year periodFull year 2023 financial summaryRevenues of $2,974.5 million, up 6.6% year-over-year; up 6.5% on a constant currency basisGAAP diluted EPS from continuing operations of $7.56, compared to $7.67 in the prior yearAdjusted diluted EPS from continuing operations...

STAFFORD, Texas, Feb. 22, 2024 (GLOBE NEWSWIRE) — Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on the expansion of the clinical trial into Europe. The Company’s application to expand Flamingo-01 into Europe has been reviewed by European Medicines Agency (EMA) through EMA’s Clinical Trials Information System (CTIS). The Company was informed that the manufacturing, non-clinical, clinical, statistical, and regulatory sections of its application are acceptable and the regulators’ requests for information have been addressed....

Figure 1Figure 1Figure 2Figure 2TORONTO, Feb. 22, 2024 (GLOBE NEWSWIRE) — G2 Goldfields Inc. (“G2” or the “Company”) (TSXV: GTWO; OTCQX: GUYGF) is pleased to report assay results from twenty diamond drill holes (totalling 4,783m) recently completed at the Company’s Ghanie Zone, one of several mineralized areas discovered at the 27,719-acre OKO Project, Guyana. Ghanie lies between G2’s OMZ gold discovery and Reunion Gold’s ‘Block 4’ discovery. Both projects have established the OKO Trend’s multi-million-ounce potential and are currently the subject of ongoing drilling with further resource estimates expected in March 2024. The results of this program establish significant widths of gold mineralization at both the Ghanie Central and South areas to vertical depths exceeding 260 meters and provide further evidence...

Frontline plc.’s preliminary fourth quarter 2023 results will be released on Thursday February 29, 2024, and a webcast and conference call will be held at 3:00 p.m. CET (9:00 a.m. U.S. Eastern Time). The results presentation will be available for download from the Investor Relations section at www.frontlineplc.cy ahead of the conference call. In order to attend the conference call you may do one of the following: a. WebcastGo to the Investor Relations section at www.frontlineplc.cy and follow the “Webcast” link, or access directly from the link below. Frontline plc Q4 2023 Webcast b. Conference Call Participants will need to register online prior to the conference call via the link below. Dial-in details will be available when registered.               Frontline plc Q4 2023 Conference Call A Q&A session will be held after the teleconference/webcast....

Frontline plc.’s preliminary fourth quarter 2024 results will be released on Thursday February 29, 2024, and a webcast and conference call will be held at 3:00 p.m. CET (9:00 a.m. U.S. Eastern Time). The results presentation will be available for download from the Investor Relations section at www.frontlineplc.cy ahead of the conference call. In order to attend the conference call you may do one of the following: a. WebcastGo to the Investor Relations section at www.frontlineplc.cy and follow the “Webcast” link, or access directly from the link below. Frontline plc Q4 2023 Webcast b. Conference Call Participants will need to register online prior to the conference call via the link below. Dial-in details will be available when registered.               Frontline plc Q4 2023 Conference Call A Q&A session will be held after the teleconference/webcast....

COMPANY ANNOUNCEMENT NO. 4-2024 22 February 2024, Copenhagen, DenmarkFLSmidth has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in FLSmidth made by persons discharging managerial responsibilities in FLSmidth and/or persons closely associated with them. Please see the transactions of Group CEO, Mikko Keto, and Group CFO, Roland M. Andersen, in the attached PDF document.Contacts: Investor RelationsJannick Lindegaard Denholt, +45 21 69 66 57, jli@flsmidth.comAndreas Escherich Holkjær, +45 24 85 03 84, andh@flsmidth.comTherese Möllevinge, +45 41 37 16 38, tmo@flsmidth.com Media RelationsRasmus Windfeld, +45 40 44 60 60, rwin@flsmidth.comAbout FLSmidthFLSmidth is a full flowsheet technology and service supplier to the global mining and cement industries. We enable...

ORION CORPORATION PRESS RELEASE 22 FEBRUARY 2024 at 11.00 EET                     Orion and Save the Children Finland announce cooperation to promote well-being of children in Finland and globally Orion Corporation and Save the Children Finland have signed a cooperation agreement for the year 2024. With Orion’s donation of EUR 50,000, Save the Children Finland will promote the well-being of underprivileged children and young people in Finland and the availability of vital health and nutrition services in the East African region. “At Orion, elements of social responsibility are considered from the entire value chain to the final user of the medicine, the patient. We want to take responsibility for people’s well-being not only in our own value chain, but also in society at large,” says Liisa Hurme, President and CEO...